Median overall survival for GPS and Keytruda® combination was 18.4 Months compared to 13.8 Months in a Keytruda® single agent study (KEYNOTE-028) and 11-14 Months with standard of care chemotherapy Combination of GPS and Keytruda® yielded WT1-specific T-cell immune response and correlated positively in subset of patients with IFNγ and… Read More..

POMPANO BEACH, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC:BSEM), a leading regenerative medicine company focused on the development, manufacture and commercialization of placental-derived biologics for advanced wound care, today announced that the Centers for Medicare and Medicaid Services (CMS) has published a new Q code, Q4279… Read More..

Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits were observed across a number of clinical endpoints including pruritus, Investigator skin scoring system and patient global assessment No safety concerns have been observed to date in either ongoing clinical… Read More..